Compare PGP & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGP | TIL |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.9M | 74.7M |
| IPO Year | N/A | 2021 |
| Metric | PGP | TIL |
|---|---|---|
| Price | $8.65 | $8.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | ★ 42.4K | 37.3K |
| Earning Date | 01-01-0001 | 03-03-2026 |
| Dividend Yield | ★ 10.84% | N/A |
| EPS Growth | N/A | ★ 52.54 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $6.56 | $5.67 |
| 52 Week High | $9.41 | $42.75 |
| Indicator | PGP | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 30.33 | 45.88 |
| Support Level | $8.57 | $8.14 |
| Resistance Level | $8.67 | $9.54 |
| Average True Range (ATR) | 0.18 | 0.52 |
| MACD | -0.05 | -0.07 |
| Stochastic Oscillator | 23.99 | 19.22 |
PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, and long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.